Key features and details
- Mouse monoclonal [2C10] to HSV1 + HSV2 gD
- Suitable for: WB, ELISA, ICC/IF
- Isotype: IgG2a
Product nameAnti-HSV1 + HSV2 gD antibody [2C10]
DescriptionMouse monoclonal [2C10] to HSV1 + HSV2 gD
Tested applicationsSuitable for: WB, ELISA, ICC/IFmore details
Species reactivityReacts with: Other species
Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.
Concentration information loading...
PurityProtein A purified
Light chain typekappa
Our Abpromise guarantee covers the use of ab6507 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|ICC/IF||1/3200 - 1/25600.
1/3,200 (HSV-2) - 1/25,600 (HSV-1).
RelevanceHerpes simplex virus 1 and 2 (HSV-1 and HSV-2) are two species of the herpes virus family, Herpesviridae, which cause infections in humans. They are also called Human Herpes Virus 1 and 2 (HHV-1 and HHV-2) and are neurotropic and neuroinvasive viruses; they enter and hide in the human nervous system, accounting for their durability in the human body. Under a microscope, HSV- 1 and 2 are virtually identical, sharing approximately 50% of their DNA. Both types infect the body's mucosal surfaces, usually the mouth or genitals, and then establish latency in the nervous system. HSV-1 is commonly associated with herpes outbreaks of the face known as cold sores or fever blisters, whereas HSV-2 is more often associated with genital herpes. Herpes simplex viruses (HSV) use multiple and sequential receptors to enter host cells. HSV glycoprotein D (gD) has been implicated in binding to cellular receptors that facilitate virus penetration into cells. Herpes simplex virus type 1 (HSV-1) glycoprotein D (gD) is an essential component of the entry apparatus that is responsible for viral penetration and subsequent cell-cell spread.
- Envelope glycoprotein D antibody
- GD antibody
- Glycoprotein D antibody
- US6 antibody
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
ab6507 has been referenced in 12 publications.
- Su P et al. High-brightness anterograde transneuronal HSV1 H129 tracer modified using a Trojan horse-like strategy. Mol Brain 13:5 (2020). PubMed: 31931837
- Li F et al. Amentoflavone Inhibits HSV-1 and ACV-Resistant Strain Infection by Suppressing Viral Early Infection. Viruses 11:N/A (2019). PubMed: 31121928
- Criscuolo E et al. Cell-to-Cell Spread Blocking Activity Is Extremely Limited in the Sera of Herpes Simplex Virus 1 (HSV-1)- and HSV-2-Infected Subjects. J Virol 93:N/A (2019). PubMed: 30867302
- Aravantinou M et al. Experimental Oral Herpes Simplex Virus-1 (HSV-1) Co-infection in Simian Immunodeficiency Virus (SIV)-Infected Rhesus Macaques. Front Microbiol 8:2342 (2017). ELISA . PubMed: 29259582
- Çuburu N et al. Topical herpes simplex virus 2 (HSV-2) vaccination with human papillomavirus vectors expressing gB/gD ectodomains induces genital-tissue-resident memory CD8+ T cells and reduces genital disease and viral shedding after HSV-2 challenge. J Virol 89:83-96 (2015). WB . PubMed: 25320297